Gene therapy uniQure NV (Amsterdam) reported that factor IX levels of patients with severe hemophilia B raised to a mean of 38% of normal 12 weeks after a single injection of AMT-061.
Ose Immunotherapeutics has got the first milestone payment within its €272m deal with Servier inked in 2016.
Analyses of the stroma cell proteome have revealed how intratumoral hypoxia triggers the formation of dysfunctional blood vessels that block drugs from entering the tumour and push metastasis.
Jennewein Biotechnologie and Asia’s largest dairy company Yili Group have joined forces to develop an innovative infant formula tailored to the Chinese market.
Sosei Group Corporation has spun out two programmes of its neurology pipeline into two newly created companies funded by venture fund Medicxi.
EMA’s human medicines committee (CHMP) recommended six medicines for approval at its January 2019 meeting.
Hitachi Chemical Co. Ltd. is set to takeover cell and gene therapy CDMO apceth Biopharma GmbH to get a foothold in Europe, the second largest market for advanced therapies after the US.
Dewpoint Therapeutics has attracted interested of investors with a completely new approach that might cure a huge array of devasting diseases.
Marinomed has set the offer price for its IPO at Vienna Stock Exchange at the lower limit of €75 per new share.
Novozymes has entered into a partnership with French Carbios and its subsidiary Carbiolice, which aim to launch degradable bioplastics with limited lifespan for the packaging industry by 2020.